Medipal Holdings Corp

Medipal Holdings Corp

Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (JPY)1,804.00
  • Today's Change19.00 / 1.06%
  • Shares traded594.90k
  • 1 Year change-10.47%
  • Beta0.6241
Data delayed at least 20 minutes, as of Mar 31 2023 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MEDIPAL HOLDINGS CORPORATION engages in the wholesale of pharmaceutical products, cosmetics and daily miscellaneous goods. The Company operates in three segments. The Ethical Pharmaceutical Wholesale segment is involved in the wholesale of pharmaceutical products, medical equipment and test reagents, the distribution and planning of specialty drugs, the construction of medical material database and others. The Cosmetics, Daily Product and General Medicine Wholesale segment is engaged in the wholesale of cosmetics, daily miscellaneous goods and general pharmaceuticals. The Veterinary Medicine and Food Processing Raw Materials Wholesale segment is engaged in the wholesale of veterinary products, food additives and food raw materials. The Company is also involved in the provision of cleaning services, the management and operation of logistics centers, the provision of manpower dispatching services and others.

  • Revenue in JPY (TTM)3.35tn
  • Net income in JPY30.44bn
  • Incorporated1923
  • Employees12.80k
  • Location
    Medipal Holdings Corp2-7-15, YaesuCHUO-KU 104-8461JapanJPN
  • Phone+81 335175800
  • Fax+81 335175028
  • Websitehttps://www.medipal.co.jp/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
7459:TYO since
Sumitomo Pharma Food & Chemical Co LtdAnnounced30 Nov 202230 Nov 2022Announced-2.17%313.47m
Toshichi IncAnnounced29 Jul 202229 Jul 2022Announced-12.17%56.26m
Data delayed at least 20 minutes, as of Mar 31 2023 07:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Herbalife Nutrition Ltd690.39bn42.62bn206.68bn10.10k4.89--3.570.29943.223.2252.29-12.931.872.0375.70515,287.1011.5712.3318.3920.6377.4579.336.176.640.7944.351.890.00-10.313.29-28.15-2.6410.37--
Nu Skin Enterprises, Inc.295.24bn13.90bn257.20bn3.80k18.872.1610.900.87112.082.0844.1018.131.191.6950.21585,699.805.628.187.3810.9371.6574.774.715.861.15--0.309753.39-17.44-0.4734-28.85-9.97-0.36841.35
Tibet Rhodiola Pharmaceutical Holding Co49.31bn7.14bn257.98bn615.0036.144.44--5.231.491.4910.3012.150.64661.515.564,153,836.009.5010.1213.0912.3192.9887.5414.6918.502.5541.640.138742.5919.4522.7876.9910.00-30.037.81
Suzuken Co Ltd2.31tn19.31bn289.96bn14.03k14.840.66110.570.1257221.97221.9726,413.144,985.061.7813.044.05164,380,000.001.491.754.364.597.748.210.8360.92391.00--0.0031.844.910.975482.31-7.552.145.92
GuangYuYuan Chinese Herbal Medicn Co Ltd20.86bn-4.93bn335.82bn1.90k--8.49--16.10-0.5216-0.52162.214.190.34141.170.8856568,822.60-8.473.08-11.644.3260.0775.75-24.818.022.37-9.710.226511.21-23.00-1.83-1,088.17---36.34--
Alfresa Holdings Corporation2.67tn28.25bn341.18bn11.93k12.110.70688.200.1279138.85138.8513,147.112,379.801.8914.874.05223,746,900.002.002.635.547.047.247.401.061.331.03--0.0000229.60-0.94940.263831.350.82094.548.45
China Medicine Health Industry Co Ltd703.12bn11.16bn393.01bn8.72k35.211.88--0.55900.38650.386524.357.,179,414.001.945.004.0211.5513.2416.441.763.931.286.790.312537.30-7.836.91-50.63-7.3912.03-0.9072
Medipal Holdings Corp3.35tn30.44bn402.45bn12.80k12.770.67717.430.1201139.74139.7415,258.572,636.251.8716.614.34261,781,800.002.212.606.667.266.677.021.181.321.03--0.042426.652.481.4422.980.2824-12.037.26
Fah Mai Holdings Group Inc10.90m-58.65m517.35bn--------47,479.92-0.4413-0.44130.082304.060.000310.2953.17---0.175---0.1752--62.47---538.28--0.0079--0.3963--6.82---93.99------
China Medical System Holdings176.27bn62.78bn519.61bn5.45k8.281.857.702.951.511.514.256.780.54534.455.32--19.5219.7323.1022.2476.8974.7935.8035.222.90--0.109539.889.7511.348.0114.24--14.80
China National Medicines Corp Ltd878.30bn37.91bn522.01bn3.08k13.771.90--0.59432.602.6060.3018.841.5811.567.9414,772,270.007.397.3214.7215.588.158.304.684.191.73--0.161728.61-2.094.6311.9711.4612.1211.69
Jointown Pharmaceutical Group Co Ltd2.57tn35.10bn543.32bn29.34k15.661.26--0.21120.9590.95967.9012.941.488.763.674,542,
Data as of Mar 31 2023. Currency figures normalised to Medipal Holdings Corp's reporting currency: Japanese Yen JPY

Institutional shareholders

21.48%Per cent of shares held by top holders
HolderShares% Held
Silchester International Investors LLPas of 10 Jan 202324.99m10.22%
Nomura Asset Management Co., Ltd.as of 30 Sep 20227.37m3.01%
The Vanguard Group, Inc.as of 03 Mar 20233.75m1.54%
Norges Bank Investment Managementas of 31 Dec 20223.38m1.38%
Nikko Asset Management Co., Ltd.as of 03 Mar 20233.21m1.31%
Daiwa Asset Management Co. Ltd.as of 28 Feb 20233.18m1.30%
BlackRock Fund Advisorsas of 01 Mar 20232.11m0.86%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 02 Mar 20231.63m0.67%
Geode Capital Management LLCas of 31 Jan 20231.55m0.63%
Dimensional Fund Advisors LPas of 02 Mar 20231.36m0.56%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.